287 related articles for article (PubMed ID: 24297183)
1. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.
Sun F; Chen HG; Li W; Yang X; Wang X; Jiang R; Guo Z; Chen H; Huang J; Borowsky AD; Qiu Y
J Biol Chem; 2014 Jan; 289(3):1529-39. PubMed ID: 24297183
[TBL] [Abstract][Full Text] [Related]
2. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
3. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
Kong D; Sethi S; Li Y; Chen W; Sakr WA; Heath E; Sarkar FH
Prostate; 2015 Feb; 75(2):161-74. PubMed ID: 25307492
[TBL] [Abstract][Full Text] [Related]
5. Regulation of androgen receptor splice variant AR3 by PCGEM1.
Zhang Z; Zhou N; Huang J; Ho TT; Zhu Z; Qiu Z; Zhou X; Bai C; Wu F; Xu M; Mo YY
Oncotarget; 2016 Mar; 7(13):15481-91. PubMed ID: 26848868
[TBL] [Abstract][Full Text] [Related]
6. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
7. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
9. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
12. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.
Li Y; Hwang TH; Oseth LA; Hauge A; Vessella RL; Schmechel SC; Hirsch B; Beckman KB; Silverstein KA; Dehm SM
Oncogene; 2012 Nov; 31(45):4759-67. PubMed ID: 22266865
[TBL] [Abstract][Full Text] [Related]
13. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Yang X; Guo Z; Sun F; Li W; Alfano A; Shimelis H; Chen M; Brodie AMH; Chen H; Xiao Z; Veenstra TD; Qiu Y
J Biol Chem; 2011 Oct; 286(41):36152-36160. PubMed ID: 21878636
[TBL] [Abstract][Full Text] [Related]
14. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of the androgen receptor splicing in prostate cancer cells.
Liu LL; Xie N; Sun S; Plymate S; Mostaghel E; Dong X
Oncogene; 2014 Jun; 33(24):3140-50. PubMed ID: 23851510
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells.
Rana M; Dong J; Robertson MJ; Basil P; Coarfa C; Weigel NL
Sci Rep; 2021 Jan; 11(1):1393. PubMed ID: 33446905
[TBL] [Abstract][Full Text] [Related]
17. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.
Nakata D; Nakao S; Nakayama K; Araki S; Nakayama Y; Aparicio S; Hara T; Nakanishi A
Biochem Biophys Res Commun; 2017 Jan; 483(1):271-276. PubMed ID: 28025139
[TBL] [Abstract][Full Text] [Related]
18. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
[TBL] [Abstract][Full Text] [Related]
19. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
[TBL] [Abstract][Full Text] [Related]
20. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
